Basic Information | Post buying leads | Suppliers |
Name |
N,N-Diethyllysergamide |
EINECS | 200-033-2 |
CAS No. | 50-37-3 | Density | 1.216 g/cm3 |
PSA | 39.34000 | LogP | 2.84390 |
Solubility | N/A | Melting Point |
80 - 85 C |
Formula | C20H25N3O | Boiling Point | 541.279 °C at 760 mmHg |
Molecular Weight | 323.438 | Flash Point | 281.156 °C |
Transport Information | UN 2811 | Appearance | crystalline solid |
Safety | 22-28-36-45-33-24-16-7 | Risk Codes | 26/27/28-40-36/38-23/25 |
Molecular Structure | Hazard Symbols | T+, T, F | |
Synonyms |
Acid Diethylamide, Lysergic;Diethylamide, Lysergic Acid;LSD;LSD 25;LSD-25;Lysergic Acid Diethylamide;Lysergic Acid Diethylamide Tartrate;Lysergide |
The systematic name of N,N-Diethyllysergamide is (8beta)-N,N-diethyl-6-methyl-9,10-didehydroergoline-8-carboxamide. With the CAS registry number 50-37-3, it is also named as Lysergic acid diethylamide. The classification codes are Central Nervous System Agents; Drug / Therapeutic Agent; Hallucinogens; Human Data; Mutation data; Neurotransmitter Agents; Psychotropic Drugs; Reproductive Effect; Serotonin Agents; Serotonin antagonists. It is crystalline solid which is an ergoline derivative and a chiral compound. When heated to decomposition it emits toxic fumes of NOx. So the storage environment should be well-ventilated, low-temperature and dry. Keep N,N-Diethyllysergamide separate from raw materials of food.
The other characteristics of this product can be summarized as: (1)ACD/LogP: 2.71; (2)# of Rule of 5 Violations: 0; (3)ACD/LogD (pH 5.5): 0.765; (4)ACD/LogD (pH 7.4): 2.373; (5)ACD/BCF (pH 5.5): 1; (6)ACD/BCF (pH 7.4): 31.066; (7)ACD/KOC (pH 5.5): 8.051; (8)ACD/KOC (pH 7.4): 326.239; (9)#H bond acceptors: 4; (10)#H bond donors: 1; (11)#Freely Rotating Bonds: 3; (12)Polar Surface Area: 39.34 Å2; (13)Index of Refraction: 1.652; (14)Molar Refractivity: 97.224 cm3; (15)Molar Volume: 266.033 cm3; (16)Surface Tension: 55.942 dyne/cm; (17)Enthalpy of Vaporization: 81.912 kJ/mol; (18)Vapour Pressure: 0 mmHg at 25°C; (19)Rotatable Bond Count: 3; (20)Tautomer Count: 2; (21)Exact Mass: 323.199762; (22)MonoIsotopic Mass: 323.199762; (23)Topological Polar Surface Area: 39.3; (24)Heavy Atom Count: 24.
Preparation of N,N-Diethyllysergamide: It is obtained by reacting diethylamine with an activated form of lysergic acid. Activating reagents include phosphoryl chloride and peptide coupling reagents. Lysergic acid is produced by alkaline hydrolysis of lysergamides like ergotamine, a substance derived from the ergot fungus on rye, or from ergine (lysergic acid amide, LSA), a compound that is found in morning glory (Ipomoea tricolor) and Hawaiian baby woodrose (Argyreia nervosa) seeds.
Uses of N,N-Diethyllysergamide: It is a semisynthetic psychedelic drug of the ergoline family. It has been used in psychiatry for its perceived therapeutic value, in the treatment of alcoholism, pain and cluster headache relief, for spiritual purposes, and to enhance creativity. It is also used mainly as an entheogen, recreational drug, and as an agent in psychedelic therapy.
When you are using this chemical, please be cautious about it as the following:
It is not only toxic by inhalation, in contact with skin and if swallowed, but also irritating to eyes and skin. Anf it has limited evidence of a carcinogenic effect. So people should not breathe dust and avoid contact with skin. After contact with skin, wash immediately with plenty of soap-suds. If you want to contact this product, you must wear suitable protective clothing. In case of accident or if you feel unwell, seek medical advice immediately (show the label whenever possible.)
People can use the following data to convert to the molecule structure.
1. SMILES:CCN(CC)C(=O)[C@H]1CN([C@@H]2Cc3c[nH]c4c3c(ccc4)C2=C1)C
2. InChI:InChI=1/C20H25N3O/c1-4-23(5-2)20(24)14-9-16-15-7-6-8-17-19(15)13(11-21-17)10-18(16)22(3)12-14/h6-9,11,14,18,21H,4-5,10,12H2,1-3H3/t14-,18-/m1/s1
3. InChIKey:VAYOSLLFUXYJDT-RDTXWAMCBY
The following are the toxicity data which has been tested.
Organism | Test Type | Route | Reported Dose (Normalized Dose) | Effect | Source |
---|---|---|---|---|---|
bird - wild | LD50 | oral | 1800ug/kg (1.8mg/kg) | Toxicology and Applied Pharmacology. Vol. 21, Pg. 315, 1972. | |
guinea pig | LD50 | subcutaneous | 16mg/kg (16mg/kg) | Archives Internationales de Pharmacodynamie et de Therapie. Vol. 137, Pg. 375, 1962. | |
human | TDLo | intramuscular | 750ng/kg (0.00075mg/kg) | BEHAVIORAL: EUPHORIA BEHAVIORAL: "HALLUCINATIONS, DISTORTED PERCEPTIONS" | Psychopharmacologia Vol. 3, Pg. 219, 1962. |
human | TDLo | oral | 700ng/kg (0.0007mg/kg) | BEHAVIORAL: EXCITEMENT | Journal of Pharmacology and Experimental Therapeutics. Vol. 120, Pg. 340, 1957. |
human | TDLo | oral | 857ng/kg (0.000857mg/kg) | BEHAVIORAL: "HALLUCINATIONS, DISTORTED PERCEPTIONS" BEHAVIORAL: ANOREXIA (HUMAN GASTROINTESTINAL: NAUSEA OR VOMITING | Arzneimittel-Forschung. Drug Research. Vol. 16, Pg. 220, 1966. |
human | TDLo | oral | 2857ng/kg (0.002857mg/kg) | BEHAVIORAL: "HALLUCINATIONS, DISTORTED PERCEPTIONS" | "Toxicology of Drugs and Chemicals," Deichmann, W.B., New York, Academic Press, Inc., 1969Vol. -, Pg. 356, 1969. |
mouse | LD50 | intraperitoneal | 50mg/kg (50mg/kg) | National Technical Information Service. Vol. AD277-689, | |
mouse | LD50 | intravenous | 46mg/kg (46mg/kg) | International Record of Medicine. Vol. 172, Pg. 702, 1959. | |
rabbit | LD50 | intravenous | 300ug/kg (0.3mg/kg) | BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY) BEHAVIORAL: ATAXIA | Annals of the New York Academy of Sciences. Vol. 66, Pg. 668, 1957. |
rat | LD50 | intravenous | 16mg/kg (16mg/kg) | International Record of Medicine. Vol. 172, Pg. 702, 1959. |